The European Commission's Scientific Committee on Health and Environmental Risks (SCHER) recently issued an Opinion on the need for non-human primate (NHP) use in biomedical research, and the possibilities of replacing NHP use with alternatives, as part of the Directive 86/609/EEC revision process. Here, we summarise our recent complaint to the European Ombudsman about SCHER's Opinion and the entire consultation process. It is our opinion that the Working Group almost entirely failed to address its remit, and that the Group was unbalanced and contained insufficient expertise. The Opinion presumed the validity of NHP research with inadequate supporting evidence, and ignored substantial evidence against the need for NHP research and examples of valid alternatives that could replace the use of NHPs. Because the European Commission and others might base their approach to NHP research directly on the inquiry's findings during the revision of Directive 86/609/EEC, the implications of a flawed analysis of the efficacy of NHP research are extremely serious, both for animal welfare and for human health and safety. The conduct of the SCHER inquiry, and its published Opinion, should therefore be of major and widespread concern, and should not be given any political, scientific or legislative credibility.
European Commission (1986). Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Official Journal of the European UnionL358, 18.12.1986, 1–28. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31986L0609:en:HTML (Accessed 24.08.09).
AldhousP., CoghlanA. & CopleyJ. (1999). Animal experiments: Where do you draw the line? New Scientist, 22 May, No. 2187, 26–31.
4.
ECEAE (2009). Opinion Poll on Animal Experiments Launched.London, UK: European Coalition to End Animal Experiments. Available at: http://www.eceae.org/news.php?p=492&more=1 (Accessed 24.08.09).
5.
European Parliament (2007). Written Declaration Pursuant to Rule 116 of the Rules of Procedure by Jens Holm, Rebecca Harms, John Bowis, Martine Roure and Mojca Drčar Murko on Primates in Scientific Experiments (0040/2007), 2 pp. Brussels, Belgium: European Parliament. Available at: http://ec.europa.eu/environment/chemicals/lab_animals/pdf/declaration_nhp_en.pdf (Accessed 24.08.09).
6.
SCHER (2009). The Need for Non-human Primates in Biomedical Research, Production and Testing of Products and Devices, 38 pp. Brussels, Belgium: Scientific Committee on Health and Environmental Risks, European Commission, Health & Consumer Protection DG. Available at: http://ec.europa.eu/health/ph_risk/committees/04_scher/docs/scher_o_110.pdf (Accessed 24.08.09).
KhetaniS.R. & BhatiaS.N. (2008). Microscale culture of human liver cells for drug development. Nature Biotechnology26, 120–126.
12.
HewittN.J., BühringK.U., DasenbrockJ., HaunschildJ., LadstetterB. & UteschD. (2001). Studies comparing in vivo: in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug Metabolism & Disposition: The Biological Fate of Chemicals29, 1042–1050.
ElkayamT., Amitay-ShaprutS., Dvir-GinzbergM., HarelT. & CohenS. (2006). Enhancing the drug metabolism activities of C3A — a human hepatocyte cell line — by tissue engineering within alginate scaffolds. Tissue Engineering12, 1357–1368.
15.
TohY.C., ZhangC., ZhangJ., KhongY.M., ChangS., SamperV.D., van NoortD., HutmacherD.W. & YuH. (2007). A novel 3D mammalian cell perfusion-culture system in microfluidic channels. Lab on a Chip7, 302–309.
16.
KimuraH., YamamotoT., SakaiH., SakaiY. & FujiiT. (2008). An integrated microfluidic system for long-term perfusion culture and on-line monitoring of intestinal tissue models. Lab on a Chip8, 741–746.
ByersA.M., TapiaT.M., SassanoE.R. & WittmanV. (2009). In vitro antibody response to tetanus in the MIMIC system is a representative measure of vaccine immunogenicity. Biologicals37, 148–151.
GottweinJ.M. & BukhJ. (2008). Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Advances in Virus Research71, 51–133.
23.
GershonD. (2002). Malaria research tools up for the future. Nature, London419, 4–5.
24.
SattabongkotJ., YimamnuaychokeN., LeelaudomlipiS., RasameesorajM., JenwithisukR., ColemanR.E., UdomsangpetchR., CuiL. & BrewerT.G. (2006). Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. American Journal of Tropical Medicine & Hygiene74, 708–715.
25.
NguyenT.V., FujiokaH., KangA.S., RogersW.O., FidockD.A. & JamesA.A. (2001). Stage-dependent localization of a novel gene product of the malaria parasite, Plasmodium falciparum. Journal of Biological Chemistry276, 26724–26731.
26.
PetersJ., FowlerE., GattonM., ChenN., SaulA. & ChengQ. (2002). High diversity and rapid changeover of expressed var genes during the acute phase of Plasmodium falciparum infections in human volunteers. Proceedings of the National Academy of Sciences of the USA99, 10689–10694.
27.
LuZ., DouthittM.P., TaffsR.E., RanY., NorwoodL.P. & ChumakovK.M. (1993). Quantitative aspects of the mutant analysis by PCR and restriction enzyme cleavage (MAPREC). PCR Methods & Applications3, 176–180.
28.
WHO Expert Committee on Biological Standardization (1999). 48th Report: World Health Organization Technical Report Series889, i–vi, 1–111. Geneva, Switzerland: World Health Organization. Available at: http://whqlibdoc.who.int/trs/WHO_TRS_889.pdf (Accessed 24.08.09).
29.
AscherioA., ChenH., WeisskopfM.G., O'ReillyE., McCulloughM.L., CalleE.E., SchwarzschildM.A. & ThunM.J. (2006). Pesticide exposure and risk for Parkinson's disease. Annals of Neurology60, 197–203.
30.
BrückA., PortinR., LindellA., LaihinenA., BergmanJ., HaaparantaM., SolinO. & RinneJ.O. (2001). Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neuroscience Letters311, 81–84.
BoscoloE., PavesiG., ZampieriP., ConconiM.T., CaloreC., ScienzaR., ParnigottoP.P. & FolinM. (2006). Endothelial cells from human cerebral aneurysm and arteriovenous malformation release ET-1 in response to vessel rupture. International Journal of Molecular Medicine18, 813–819.
33.
JinK., WangX., XieL., MaoX.O., ZhuW., WangY., ShenJ., MaoY., BanwaitS. & GreenbergD.A. (2006). Evidence for stroke-induced neurogenesis in the human brain. Proceedings of the National Academy of Sciences of the USA103, 13198–13202.
34.
NorabergJ., PoulsenF.R., BlaabjergM., KristensenB.W., BondeC., MonteroM., MeyerM., GramsbergenJ.B. & ZimmerJ. (2005). Organotypic hippocampal slice cultures for studies of brain damage, neuroprotection and neurorepair. Current Drug Targets. CNS & Neurological Disorders4, 435–452.
35.
GoldJ.J., SmithC.N., BayleyP.J., ShragerY., BrewerJ.B., StarkC.E., HopkinsR.O. & SquireL.R. (2006). Item memory, source memory, and the medial temporal lobe: concordant findings from fMRI and memory-impaired patients. Proceedings of the National Academy of Sciences of the USA103, 9351–9356.
36.
ShragerY., BayleyP.J., BontempiB., HopkinsR.O. & SquireL.R. (2007). Spatial memory and the human hippocampus. Proceedings of the National Academy of Sciences of the USA104, 2961–2966.
37.
MurphyP.J., DuncanA.L., GlennieA.J. & KnoxP.C. (2001). The effect of scleral search coil lens wear on the eye. The British Journal of Ophthalmology85, 332–335.
38.
McAuleyJ.H., RothwellJ.C. & MarsdenC.D. (1999). Human anticipatory eye movements may reflect rhythmic central nervous activity. Neuroscience94, 339–350.
39.
QuirogaR.Q., ReddyL., KreimanG., KochC. & FriedI. (2005). Invariant visual representation by single neurons in the human brain. Nature, London435, 1102–1107.
40.
VannucciM., PezerN., HelmstaedterC., SchallerK., ViggianoM.P., ElgerC.E. & GrunwaldT. (2008). Hippocampal response to visual objects is related to visual memory functioning. Neuroreport19, 965–968.
41.
JohnsonE.J. & GoldsteinD. (2003). Medicine. Do defaults save lives? Science, New York302, 1338–1339.
42.
Anon. (2000). Alternatives to Xenotransplantation. Campaign for Responsible Transplantation (CRT). Available at: http://www.crt-online.org/solutions.html (Accessed 24.08.09).
43.
AwuondaM. (1996). Swedish organ-donation law takes effect. The Lancet348, 54.
44.
NicholsonM.L. & BradleyJ.A. (1999). Renal trans plantation from living donors. British Medical Journal318, 409–410.
OsterG. & ThompsonD. (1996). Estimated effects of reducing dietary saturated fat intake on the incidence and costs of coronary heart disease in the United States. Journal of the American Dietetic Association96, 127–131.
47.
RobinsonS., DelongeasJ.L., DonaldE., DreherD., FestagM., KervynS., LampoA., NahasK., NoguesV., OckertD., QuinnK., OldS., PickersgillN., SomersK., StarkC., SteiP., WatersonL. & ChapmanK. (2008). A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regulatory Toxicology & Pharmacology: RTP50, 345–352.
48.
ICH (1993). ICH Harmonised Tripartite Guideline: Detection of Toxicity to Reproduction for Medicinal Products and Toxicity to Male Fertility, S5(R2), 24 pp. (1993). Geneva Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at: http://www.ich.org/LOB/media/MEDIA498.pdf (Accessed 24.08.09).
MatthewsR.A. (2008). Medical progress depends on animal models — doesn't it? Journal of the Royal Society of Medicine101, 95–98.
51.
SpanhaakS., CookD., BarnesJ. & ReynoldsJ. (2008). Species Concordance for Liver Injury: From the Safety Intelligence Program Board, 6 pp. Cambridge, UK: BioWisdom, Ltd. Available at: http://www.biowisdom.com/files/SIP_Board_Species_Concordance.pdf (Accessed 24.08.09).
52.
da SilvaL.J. & RichtmannR. (2006). Vaccines under development: group B streptococcus, herpeszoster, HIV, malaria and dengue. Jornal de Pediatria82, S115–24.
53.
TonksA. (2007). Quest for the AIDS vaccine. British Medical Journal334, 1346–1348.
54.
D'SouzaM.P., AllenM., SheetsR. & JohnstonM.I. (2004). Current advances in HIV vaccines. Current HIV/AIDS Reports1, 18–24.
55.
JohnstonM.I. (2000). The role of nonhuman primate models in AIDS vaccine development. Molecular Medicine Today6, 267–270.
56.
TaylorK. (2006). Still Dying of Ignorance? 25 Years of Failed Primate AIDS Research. A Report by the BUAV, 16 pp. London, UK: British Union for the Abolition of Vivsection. Available at: http://www.buav.org/media/files/References/BUAV_Report-AIDs.pdf (Accessed 24.08.09).
57.
HuS.L. (2005). Non-human primate models for AIDS vaccine research. Current Drug Targets. Infectious Disorders5, 193–201.
58.
LevyY. (2005). Therapeutic HIV vaccines: an update. Current HIV/AIDS Reports2, 5–9.
59.
ToniniT., BarnettS., DonnellyJ. & RappuoliR. (2005). Current approaches to developing a preventative HIV vaccine. Current Opinion in Investigational Drugs6, 155–162.
60.
BaileyJ. (2008). An assessment of the role of chimpanzees in AIDS vaccine research. ATLA36, 381–428.
61.
BaileyJ. (2005). Non-human primates in medical research and drug development: a critical review. Biogenic Amines19, 235–256.
62.
DuverlieG. & WychowskiC. (2007). Cell culture systems for the hepatitis C virus. World Journal of Gastroenterology: WJG13, 2442–2445.
63.
MartinM.J., RaynerJ.C., GagneuxP., BarnwellJ.W. & VarkiA. (2005). Evolution of human-chimpanzee differences in malaria susceptibility: relationship to human genetic loss of N-glycolyl-neuraminic acid. Proceedings of the National Academy of Sciences of the USA102, 12819–12824.
64.
HeppnerD.G., CummingsJ.F., OckenhouseC., KesterK.E., LyonJ.A. & GordonD.M. (2001). New World monkey efficacy trials for malaria vaccine development: critical path or detour? Trends in Parasitology17, 419–425.
65.
AkhtarA.Z., PippinJ.J. & SanduskyC.B. (2008). Animal models in spinal cord injury: a review. Reviews in the Neurosciences19, 47–60.
66.
HuangJ., MoccoJ., ChoudhriT.F., PoisikA., PopilskisS.J., EmersonR., DelaPazR.L., KhandjiA.G., PinskyD.J. & ConnollyE.S.Jr (2000). A modified transorbital baboon model of reperfused stroke. Stroke31, 3054–3063.
67.
O'CollinsV.E., MacleodM.R., DonnanG.A., HorkyL.L., van der WorpB.H. & HowellsD.W. (2006). 1,026 experimental treatments in acute stroke. Annals of Neurology59, 467–477.
68.
Anon. (2006). Neuroprotection: the end of an era? The Lancet368, 1548.
69.
EmerichD.F., DeanR.L. & SanbergP.R. (eds) (2000). Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic, 532 pp. New York, NY, USA: Humana Press.
70.
NelsonE.E. & WinslowJ.T. (2009). Non-human primates: model animals for developmental psychopathology. Neuropsychopharmacology34, 90–105.
71.
BaileyL.L. (2005). Candid observations on the current status of xenotransplantation. Xenotransplantation12, 428–431.
